AI Article Synopsis
- Circulating extracellular vesicles (EVs) from epithelial ovarian cancer (EOC) patients show potential as non-invasive biomarkers for diagnosis, with a focus on their biological functions compared to healthy controls.
- A quantitative proteomic analysis revealed that 200 proteins were upregulated and 208 downregulated in EOC patients, with the complement and coagulation cascades being the most significantly affected pathway.
- The study identified specific proteins (ApoE, EpCAM, plg, serpinC1, and C1q) as optimal diagnostic indicators, achieving a high AUC score, and found elevated levels of activated Factor X in EOC patients, indicating a link between EVs and coagulation processes in late-stage ovarian cancer.
Article Abstract
Background: Circulating extracelluar vesicles (EVs) in epithelial ovarian cancer (EOC) patients emanate from multiple cells. These EVs are emerging as a new type of biomarker as they can be obtained by non-invasive approaches. The aim of this study was to investigate circulating EVs from EOC patients and healthy women to evaluate their biological function and potential as diagnostic biomarkers.
Methods: A quantitative proteomic analysis (iTRAQ) was applied and performed on 10 EOC patients with advanced stage (stage III-IV) and 10 controls. Twenty EOC patients and 20 controls were applied for validation. The candidate proteins were further validated in another 40-paired cohort to investigate their biomarker potential. Coagulation cascades activation was accessed by determining Factor X activity.
Results: Compared with controls, 200 proteins were upregulated and 208 proteins were downregulated in the EOC group. The most significantly involved pathway is complement and coagulation cascades. ApoE multiplexed with EpCAM, plg, serpinC1 and C1q provide optimal diagnostic information for EOC with AUC = 0.913 (95% confidence interval (CI) =0.848-0.957, p < 0.0001). Level of activated Factor X was significantly higher in EOC group than control (5.35 ± 0.14 vs. 3.69 ± 0.29, p < 0.0001).
Conclusions: Our study supports the concept of circulating EVs as a tool for non-invasive diagnosis of ovarian cancer. EVs also play pivotal roles in coagulation process, implying the inherent mechanism of generation of thrombus which often occurred in ovarian cancer patients at late stages.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852975 | PMC |
| http://dx.doi.org/10.1186/s12885-019-6176-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial.
Nat Med
January 2025
BioNTech US, Cambridge, MA, USA.
New treatment approaches are warranted for patients with advanced melanoma refractory to immune checkpoint blockade (ICB) or BRAF-targeted therapy. We designed BNT221, a personalized, neoantigen-specific autologous T cell product derived from peripheral blood, and tested this in a 3 + 3 dose-finding study with two dose levels (DLs) in patients with locally advanced or metastatic melanoma, disease progression after ICB, measurable disease (Response Evaluation Criteria in Solid Tumors version 1.1) and, where appropriate, BRAF-targeted therapy.
View Article and Find Full Text PDFPRP Injections for the Treatment of Knee Osteoarthritis: The Improvement Is Clinically Significant and Influenced by Platelet Concentration: A Meta-analysis of Randomized Controlled Trials.
Am J Sports Med
January 2025
Service of Orthopaedics and Traumatology, Department of Surgery, EOC, Lugano, Switzerland.
Background: Platelet-rich plasma (PRP) has emerged as a promising therapeutic intervention for knee osteoarthritis (OA), attracting substantial clinical and research attention. However, the clinical relevance of the treatment benefit remains controversial.
Purpose: To evaluate the effectiveness of PRP compared with placebo in patients with knee OA in terms of minimal clinically important difference (MCID) and to investigate the possible influence of platelet concentration on the clinical outcome.
Sensory preservation in reduction mammoplasty using the nipple-areola complex-carrying pedicle technique for gigantomastia: A systematic review and meta-analysis.
JPRAS Open
March 2025
Department of Plastic, Reconstructive and Aesthetic Surgery, Ospedale Regionale di Lugano, Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland.
Background: Gigantomastia is a disabling condition characterized by excess breast tissue. Historically, free nipple graft (FNG) has been preferred, prioritizing the nipple-areola complex (NAC) vascularity. The NAC-carrying pedicle technique, which is most commonly used in case of hypertrophy of the breast, has been suggested as a viable alternative for gigantomastia according to recent evidence, with reduced rates of NAC necrosis and improved outcomes.
View Article and Find Full Text PDFClinical Profiles and Survival Outcomes of Patients With Relapsed Ovarian Cancer: A Single-Center Study.
Cureus
November 2024
Medical Oncology, Madras Medical College, Chennai, IND.
Background Ovarian cancer is the third most prevalent form of cancer among women in India. The majority of patients are diagnosed at an advanced stage. Many women with late-stage ovarian cancer experience a recurrence and need subsequent treatment, even after initial therapy.
View Article and Find Full Text PDFLumbar Facet Joint Radiofrequency Ablation With a 3-Tined Cannula: A Technical Report and Observational Study.
Pain Res Manag
December 2024
Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland.
Lumbar facet joints are the source of pain in 15%-41% of individuals experiencing low back pain (LBP). Conventional lumbar facet radiofrequency ablation (RFA) has Level II evidence for improving pain and function. The best proven technique, the parallel technique, is technically challenging, time-consuming, and often uncomfortable for the patient.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!